Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Disease area: Respiratory infections

Abstract

The aim of the study was to examine the frequency of MBT detection and the spectrum of primary drug resistance in HIV-positive patients with TB depending on the degree of immunosuppression.
A study of 304 HIV-positive new TB cases registered during 2006-2010 with median CD4 count 140 cells/μl was carried out in TB Hospital #7 (Moscow, Russian Federation). The mean age was 31,6±6,4 years.
Etiologic confirmation of TB was obtained in 56,9% of patients (n=173), including those from sputum (35,2%, n=107), and the rest (n=66) from other materials (exudate, urine, cerebrospinal fluid, discharge from the fistula, biopsy material). Patients with CD4+ <100 cells/μl and with CD4+>350 cells/μl were found to be smear and/or culture positive more frequently (42,7%, n=53 and 42,0%, n=18 respectively) than those with CD4+ 100-349 cells/μl (26,2%, n=36) (p<0,05).
Drug susceptibility test was conducted in 126 patients on Löwenstein-Jensen media using absolute concentration method. MBT were susceptible in 48,4% of patients (n=61). 7,1% of isolates were monoresistant, polyresistance was found in 15,1% (n=19) (in most cases to combination of streptomycin or isoniazid – 57,9%).
MDR TB was detected in 29,4% of patients (n=37) (including 4 cases of XDR, 3,2%). It should be noted that MDR was recorded in 35,4% of patients with CD4 + lymphocytes <200 cells/μl (28 out of 79), whereas the level of MDR in patients with CD4+ >200 cells/μl was 19,2% (9 out of 47) (p<0,05). Resistance to fluoroquinolones was registered in 7,1%.
Conclusion: Primary MDR was detected in every 3^rd HIV/TB patient. The results of the study suggest the frequency of MBT detection from sputum in HIV/TB patients, as well as frequency of MDR, depends on the degree of immunosuppression.

Rating:

Share or cite this content

Citations should be made in the following way:
V. Zimina, I. Vasilyeva, A. Kravtchenko, F. Batirov, I. Viktorova (Moscow, Novokuznetsk, Russian Federation). Primary drug resistance in HIV/TB patients. Eur Respir J 2011; 38: Suppl. 55, 1937

Member's Comments

No comment yet.

Related content which might interest you: Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Primary and acquired drug resistance in childhood tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 653s Year: 2005 Burden of the primary drug resistance of Mycobacterium tuberculosis in HIV-positive patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Bedaquiline in treatment of TB/HIV co-infection patients with extremely-drug resistance of MBT Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Primary drug resistance in HIV/tuberculosis patients in two large cities of Siberia Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016 Primary drug resistance rates in pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 42s Year: 2003 Medico-social features of resistance development to new anti–TB drugs in patients with MDR/XDR TB Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 Effectiveness of the intensive phase of chemotherapy in pulmonary TB patients with primary drug resistance Source: Eur Respir J 2006; 28: Suppl. 50, 290s Year: 2006 Predictors of death in patients with MDR-TB and HIV Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Prevalance of initial and acquired resistance to antituberculosis drugs in our clinic Source: Eur Respir J 2005; 26: Suppl. 49, 653s Year: 2005 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Primary drug resistance in pulmonary tuberculosis Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Antituberculosis drug resistance rates in patients newly diagnosed with TB in Istanbul Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012 Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019 Year: 2020 Antituberculous drug resistance rates in soldier patients newly diagnosed with TB in Turkey Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Immunologic recovery in HIV/TB co-infected patients after anti-TB treatment Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 First line anti-tuberculous drug resistance prevalence and its pattern among HIV infected patients in the national referral TB center, Iran Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009